Evidence map›Paper›PMID 29382030›Full record

ReviewMedicine2017

A recurrence-free survivor with chemotherapy-refractory small cell lung cancer after pneumonectomy: A case report and review of the literature.

Yong Pan, Feng-Wei Kong, Heng Wang, Xiang Wang, Hui Zhang, Wen-Bin Wu, Miao Zhang

Open access · goldAbstract readCase ReportsReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Medicine, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
0.2field-weighted citation impact, top 40% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 4 citations in OpenAlex.

  1. Review
  2. Review
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 1 institution in 1 country.

Yong PanDepartment of General Surgery, Xuzhou Infectious Disease Hospital, Xuzhou, China Department of Thoracic Surgery Department of Oncology, Xuzhou Central Hospital Affiliated to Southeast University, Xuzhou, China.
Feng-Wei Kong
Heng Wang
Xiang Wang
Hui Zhang
Wen-Bin Wu
Miao Zhang
Jiangsu University · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

rationaleThe optimal therapeutic regimen for chemotherapy-refractory and node-positive small-cell lung cancer (SCLC) is criticizable for the lack of evidence. PATIENT CONCERNS: A patient with locally advanced SCLC was insensitive to the first-line chemotherapy of etoposide, irinotecan, and cisplatin. DIAGNOSES: The patient was diagnosed as SCLC with mediastinal lymph node metastasis by pathological staining.

interventionsSalvage pneumonectomy and systematic lymph node dissection combined with oral apatinib and mediastinal radiotherapy were performed for him. OUTCOMES: The patient survived for more than 2 years without recurrence after the operation and adjuvant therapy. LESSONS: For patients with chemotherapy-resistant but resectable SCLC, a timely resection combined with postoperative radiotherapy and apatinib might be effective.

Indexed as

Antineoplastic Combined Chemotherapy ProtocolsChemotherapy, AdjuvantHumansLung NeoplasmsLymph Node ExcisionLymph NodesMaleMediastinumMiddle AgedNeoplasm Recurrence, LocalPneumonectomyPyridinesRadiotherapy, AdjuvantSalvage TherapySmall Cell Lung CarcinomaapatinibPyridines

Identifiers

PMID29382030
PMCPMC5709029
OpenAlexW2769416875

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.